Rowett spin-out NovaBiotics Enters into Agreement with Taro

Rowett spin-out NovaBiotics Enters into Agreement with Taro

NovaBiotics Ltd - the Aberdeen-based clinical-stage biotechnology company originally spun out of the Rowett Institute of Nutrition and Health, now part of the University of Aberdeen - today announced that it has entered into an exclusive agreement with Taro Pharmaceuticals North America, Inc. to licence and co-develop Novexatin®, NovaBiotics' first-in-class antifungal peptide treatment for fungal nail infections.

Novexatin® is an investigational drug that is expected to enter a multi-centre Phase IIb study for mild-to-moderate onychomycosis in the US.   NovaBiotics and Taro will jointly manage the study and other development activities for Novexatin®, with Taro as lead partner in the programme.

Dr. Deborah O’Neil, CEO and Scientific Officer of NovaBiotics, said: "Novexatin® is an antifungal technology that has the potential to positively affect the onychomycosis space with the key advantage of delivering results within a short treatment period of 28 days. As a leader in dermatology, Taro is an excellent fit for NovaBiotics and our ambitions for Novexatin®."

Search News

Browse by Month

2017

  1. Jan
  2. Feb
  3. Mar
  4. Apr
  5. May
  6. Jun
  7. Jul
  8. Aug
  9. Sep
  10. Oct
  11. Nov There are no items for November 2017
  12. Dec There are no items for December 2017